Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association
- PMID: 34398691
- PMCID: PMC8649306
- DOI: 10.1161/JAHA.121.021002
Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association
Abstract
Background Recently there has been increased interest in a possible association between mast cell activation (MCA) disorder and postural orthostatic tachycardia syndrome (POTS). This study examined the frequency with which symptoms and laboratory findings suggesting MCA disorder occurred in patients diagnosed with POTS. Methods and Results Data were obtained from patients in whom symptoms and orthostatic testing were consistent with a POTS diagnosis. Individuals with <4 months symptom duration, evident ongoing inflammatory disease, suspected volume depletion, or declined consent were excluded. All patients had typical POTS symptoms; some, however, had additional nonorthostatic complaints not usually associated with POTS. The latter patients underwent additional testing for known MCA biochemical mediators including prostaglandins, histamine, methylhistamine, and plasma tryptase. The study comprised 69 patients who met POTS diagnostic criteria. In 44 patients (44/69, 64%) additional nonorthostatic symptoms included migraine, allergic complaints, skin rash, or gastrointestinal symptoms. Of these 44 patients, 29 (66%) exhibited at least 1 laboratory abnormality suggesting MCA disorder, and 11/29 patients had 2 or more such abnormalities. Elevated prostaglandins (n=16) or plasma histamine markers (n=23) were the most frequent findings. Thus, 42% (29/69) of patients initially diagnosed with POTS exhibited both additional symptoms and at least 1 elevated biochemical marker suggesting MCA disorder. Conclusions Laboratory findings suggesting MCA disorder were relatively common in patients diagnosed with POTS and who present with additional nonorthostatic gastrointestinal, cutaneous, and allergic symptoms. While solitary abnormal laboratory findings are not definitive, they favor MCA disorder being considered in such cases.
Keywords: biochemical mediators; histamine; mast cell; postural orthostatic tachycardia syndrome; prostaglandins.
Conflict of interest statement
Dr Benditt reports consulting fees from Medtronic Inc and St Jude Medical. Dr Fedorowski reports consulting fees from Medtronic Inc. and Biotronik Inc. Dr Olshansky reports consulting fees from Amarin, Boehringer Ingelheim, Sanofi Aventis, Respicardia, and Lundbeck Inc.
Figures
References
-
- Sheldon RS, Grubb BP, Olshansky B, Shen W‐K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo CA, Stewart JM, et al. Heart Rhythm Society Expert Consensus Statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia and vasovagal syncope. Heart Rhythm. 2015;12:e41–e63. - PMC - PubMed
-
- Raj SR, Guzman JC, Harvey P, Richer L, Schondorf R, Seifer C, Thibodeau‐Jarry N, Sheldon RS. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. Can J Cardiol. 2020;36:357–372. DOI: 10.1016/j.cjca.2019.12.024. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous